Lupin Launches Dapagliflozin Tablets in the United States
Global pharmaceutical major Lupin Limited announced the launch of Dapagliflozin Tablets, available in 5 mg and 10 mg strengths, in the United States. This launch follows the approval of the company's Abbreviated New Drug Application from the U.S. FDA. The approval established that the tablets are bioequivalent to Farxiga® for the indications listed in the approved labeling.Lupin Limited, headquartered in Mumbai, India, specializes in a range of pharmaceutical products. These include branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a presence in over 100 markets globally.
Lupin's strong position extends across multiple therapy areas in both India and the U.S. These areas include respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. The company operates 15 state-of-the-art manufacturing sites and 7 research centers internationally. Lupin is supported by a workforce exceeding 24,000 professionals and is committed to improving patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LUPIN Stock Price Movement
Today, Lupin Limited shares edged higher, settling at ₹2333.8 after climbing 1.69%. The stock traded on a volume of 1.27 million shares, moving during the day's session between a low of ₹2290.1 and a high of ₹2336.4.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.